SequelSEC

Indivior Pharmaceuticals, Inc. INDV

Pharmaceutical Preparations · CIK 0001625297 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.33B
Fiscal year ended 2026-06-30
Operating income
$421.00M
Fiscal year ended 2026-06-30
Free cash flow
-$111.00M
Fiscal year ended 2026-06-30

Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.33B and net income of $355.00M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Indivior Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Indivior Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.33B
Cost of revenue$240.00M
Gross profit$1.09B
Operating income$421.00M
Net income$355.00M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income$393.00M
Income tax expense$38.00M
Diluted EPSUnavailable
Selling, general & administrative$590.00M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Indivior Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$222.00M
Total assets$1.23B
Current assets$725.00M
Total liabilities$1.44B
Current liabilities$868.00M
Total equity incl. NCI-$208.00M
Temporary (mezzanine) equityUnavailable
Inventory$150.00M
Accounts receivable$271.00M
GoodwillUnavailable
Long-term debt$487.00M
Accounts payable$30.00M

Cash flow

Indivior Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$40.00M
Capital expenditures$71.00M
Investing cash flow-$71.00M
Financing cash flow-$174.00M
Net change in cashUnavailable
Stock-based compensation$32.00M
Common dividends paidUnavailable
Common share repurchases$302.00M
Depreciation & amortization$9.00M

Derived

Indivior Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$111.00M
Gross margin82.1%
Operating margin31.6%
FCF margin-8.3%
SBC / revenue2.4%
Current ratio0.84x
Revenue YoY growth13.5%
Net margin26.7%
R&D / revenueUnavailable
CapEx / revenue5.3%
Long-term debt / equityUnavailable
Effective tax rate9.7%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open INDV in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.